Triple Negative Breast Neoplasms
"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Descriptor ID |
D064726
|
| MeSH Number(s) |
C04.588.180.788 C17.800.090.500.788
|
| Concept/Terms |
Triple Negative Breast Neoplasms- Triple Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Neoplasms
- ER Negative PR Negative HER2 Negative Breast Neoplasms
- Triple-Negative Breast Cancer
- Breast Cancer, Triple-Negative
- Breast Cancers, Triple-Negative
- Triple-Negative Breast Cancers
- Triple-Negative Breast Neoplasm
- Breast Neoplasm, Triple-Negative
- Breast Neoplasms, Triple-Negative
- Triple Negative Breast Neoplasm
- Triple-Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Cancer
- ER Negative PR Negative HER2 Negative Breast Cancer
- Triple Negative Breast Cancer
|
Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".
This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 2 | 0 | 2 |
| 2014 | 6 | 0 | 6 |
| 2015 | 6 | 0 | 6 |
| 2016 | 5 | 0 | 5 |
| 2017 | 4 | 1 | 5 |
| 2018 | 5 | 2 | 7 |
| 2019 | 13 | 1 | 14 |
| 2020 | 9 | 2 | 11 |
| 2021 | 7 | 2 | 9 |
| 2022 | 11 | 0 | 11 |
| 2023 | 10 | 1 | 11 |
| 2024 | 10 | 1 | 11 |
| 2025 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.
-
Lineage Tracing and Single-Cell RNA Sequencing Reveal a Common Transcriptional State in Breast Cancer Tumor-Initiating Cells Characterized by IFN/STAT1 Activity. Cancer Res. 2025 Apr 15; 85(8):1390-1409.
-
Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. Immunity. 2025 Apr 08; 58(4):909-925.e7.
-
ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer. Mol Ther. 2025 Apr 02; 33(4):1621-1641.
-
Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18; 6(2):101941.
-
Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer. Sci Rep. 2025 01 07; 15(1):1061.
-
Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Radiol Artif Intell. 2025 Jan; 7(1):e240124.
-
Telomere length sensitive regulation of interleukin receptor 1 type 1 (IL1R1) by the shelterin protein TRF2 modulates immune signalling in the tumour microenvironment. Elife. 2024 Dec 27; 13.
-
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 2025 Feb; 210(1):179-189.
-
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Res. 2024 Nov 15; 84(22):3864-3880.
-
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status?. ESMO Open. 2024 Nov; 9(11):103973.